Ptosis and Weakness after Start of D-Penicillamine Therapy
Authors: STEVEN G. ATCHESON
Journal: Annals of Internal Medicine (1978)

Brief Reports1 December 1978Ptosis and Weakness after Start of D-Penicillamine TherapySTEVEN G. ATCHESON, M.D., JOHN R. WARD, M.D.STEVEN G. ATCHESON, M.D., JOHN R. WARD, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-6-939 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptD-penicillamine is gaining increasing acceptance worldwide for the treatment of rheumatoid arthritis, despite the drug's formidable toxic potential. Most reports of adverse reactions to penicillamine have concerned its commonly encountered skin, renal, or hematopoietic toxicity. More recently, several cases of myasthenia induced by penicillamine have been described (1-3).Our patient is 59 years old and has had active rheumatoid arthritis for more than 20 years. During the preceding year he had become progressively debilitated and developed chronic pressure sores. He was confined to bed or chair, but could stand without assistance....References1. BUCKNALLDIXONGLICKWOODLANDZUTSHI RASEJD: Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br Med J 1:600-602, 1975 CrossrefMedlineGoogle Scholar2. SEITZHOPFJANZENMEYER DHRW: Penicillamine-induzierte Myasthenie bei chronischer Polyarthritis (German, with English abstract). Dtsch Med Wochenschr 101:1153-1158, 1976 CrossrefMedlineGoogle Scholar3. GORDONBURNSIDE RJ: D-penicillamine-induced myasthenia gravis in rheumatoid arthritis. Ann Intern Med 87:578-579, 1977 LinkGoogle Scholar4. DAWKINSZILKOOWEN RPE: Penicillamine therapy, antistriational antibody, and myasthenia gravis. Br Med J 4:759-760, 1975 CrossrefMedlineGoogle Scholar5. MASTERSDAWKINSZILKOSIMPSONLEEMANLINDSTROM CRPJRJ: Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies. Am J Med 63:689-694, 1977 CrossrefMedlineGoogle Scholar6. CUCHERGOLDMAN BA: D-penicillamine-induced polymyositis in rheumatoid arthritis. Ann Intern Med 85:615-616, 1976 LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Utah Medical Center Salt Lake City, Utah PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHeavy Metal Antagonists and Miscellaneous DrugsDrug-induced ocular side effectsAnti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamineDrug-induced ocular side effectsLetters to the editorOcular myasthenia: A protean disorderRheumatic DisordersDrug-Induced Autoimmune and Hematologic DisordersRheumatic syndromes caused by antirheumatic drugsOcular myasthenia gravis after D-penicillamine administration.The pathophysiology of penicillamine-induced myasthenia gravisPenicillamine induced myasthenia reactivated by gold.Penicillamine: Review and cutaneous manifestationsd-Penicillamine-induced neuromuscular disease in guinea pigsD-Penicillamine-induced pemphigus syndromeAuto-immune complications of D-penicillamine—a possible result of zinc and magnesium depletion and of pyridoxine inactivation.Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseasesMetabolic DisordersPenicillamine-induced myasthenia gravis in progressive systemic sclerosisAdverse Effects of D-Penicillamine in Rheumatoid ArthritisHOWARD B. STEIN, M.D., A. CAROLINE PATTERSON, M.B., ROBERT C. OFFER, M.D., CHRISTOPHER J. ATKINS, M.B., ALVENA TEUFEL, R.N., HAROLD S. ROBINSON, M.D.Heavy metal antagonistsPenicillamine, its metabolism and therapeutic applications: A reviewMyasthenia and Prostaglandin E1DAVID F. HORROBIN, M.A., D.PHIL., B.M. 1 December 1978Volume 89, Issue 6Page: 939-940KeywordsAdverse reactionsDrug therapyPressure ulcersPtosisRheumatoid arthritisToxicity ePublished: 1 December 2008 Issue Published: 1 December 1978 PDF downloadLoading ...